Hyku Biosciences

Drug Discovery · Burlington, MA · Founded 2021 · Privately Held (backing)

Developer of small molecule therapeutics with novel mechanisms of action intended to inhibit proteins that drive disease progression potently. Hyku Biosciences is based in Burlington, MA and was founded in 2021. It was valued at $85 million at its seed round in Nov 2024, the last priced event on record. It has raised $70.6 million across 2 recorded rounds; the latest was a $6.6 million debt round in Dec 2025.

PMV mark · valuation
$85.0M
Oct 2026
Priced at
its seed round
Nov 2024
Total raised
$70.6M
Last round
Debt
Dec 2025
What is Hyku Biosciences worth?
$85.0MPrivateMarketView mark · Oct 2026

Valued at $85.0M at its seed round, Nov 2024. Nothing has traded since.

Free account
More of Hyku Biosciences with a free account
  • ·Watch Hyku Biosciences: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Hyku Biosciences funding history

2 rounds
DateRoundRaisedPost-money
Dec 2025Debt$6.6M▮
Nov 2024Seed Round$64.0M▮
Unlock post-money valuations

Membership and data by Private Market View

Hyku Biosciences valuation

Hyku Biosciences was valued at $85 million at its seed round in Nov 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Hyku Biosciences raised?

Hyku Biosciences has raised $70.6 million across 2 recorded rounds since 2024. The largest was a $6.6 million debt round in Dec 2025.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Indapta Therapeutics ($90 million), Sydnexis ($90 million) and Linnaeus Therapeutics ($83.1 million).

How Hyku Biosciences's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Hyku Biosciences, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Hyku Biosciences

What is Hyku Biosciences worth?
Hyku Biosciences is valued at $85.0M as of Oct 2026. Valued at $85.0M at its seed round, Nov 2024. Nothing has traded since.
How much has Hyku Biosciences raised?
Hyku Biosciences has raised $70.6M in total funding across 2 recorded rounds.
When did Hyku Biosciences last raise?
Hyku Biosciences last raised in Dec 2025 (Debt), raising $6.6M.